Edgestream Partners L.P. Takes $1.13 Million Position in Roivant Sciences Ltd. $ROIV

Edgestream Partners L.P. bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the first quarter, HoldingsChannel.com reports. The fund bought 40,807 shares of the company’s stock, valued at approximately $1,130,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA lifted its stake in Roivant Sciences by 790.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after purchasing an additional 2,052,693 shares during the period. Capricorn Fund Managers Ltd grew its stake in shares of Roivant Sciences by 124.4% in the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock valued at $9,667,000 after purchasing an additional 247,000 shares during the period. Vanguard Group Inc. grew its stake in shares of Roivant Sciences by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after purchasing an additional 3,254,113 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Roivant Sciences by 90.9% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company’s stock worth $1,746,000 after buying an additional 38,354 shares in the last quarter. Finally, Nicholas Investment Partners LP raised its holdings in shares of Roivant Sciences by 13.9% in the 4th quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock worth $6,073,000 after buying an additional 34,235 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the completion of the transaction, the director directly owned 13,701,546 shares in the company, valued at $473,388,414.30. This trade represents a 5.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 2,055,913 shares of company stock worth $69,639,633. Company insiders own 8.80% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on ROIV. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a research report on Friday. Citigroup lifted their price objective on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Guggenheim lifted their price objective on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. TD Cowen boosted their target price on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.59.

Roivant Sciences Stock Down 1.7%

Roivant Sciences stock opened at $33.32 on Tuesday. The business’s 50-day simple moving average is $32.70 and its 200 day simple moving average is $29.17. The stock has a market cap of $23.97 billion, a price-to-earnings ratio of -55.53 and a beta of 1.12. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.